BIOMAT Database Logo BIOMAT Database Logo

Hodgkin's disease of donor origin after allogeneic bone marrow transplantation for myelogeneous chronic leukemia. 1998

V Meignin, and A Devergie, and P Brice, and O Brison, and N Parquet, and P Ribaud, and I Cojean, and P Gaulard, and E Gluckman, and G Socie, and A Janin
Department of Pathology, Hôpital Saint-Louis, Paris, France.

Secondary malignancies (lymphomas, leukemias, and solid tumors) occurring after bone marrow transplantation are now more frequently reported, as the patients surviving the early phase of the graft and remaining free of their original disease are more numerous. Besides early Epstein-Barr virus-associated B-cell lymphoproliferative diseases, which are the most common type and most often of donor origin, few late-occurring lymphomas have been described that might represent a distinct entity. We report here a case of Hodgkin's disease developing 8 years after allogeneic bone marrow transplantation for chronic myelogeneous leukemia. Only two Hodgkin's diseases after allogeneic bone marrow transplantation have been reported in the literature so far. The case we report is of interest because of its donor origin and its association with Epstein-Barr virus infection.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008297 Male Males
D008479 Mediastinal Neoplasms Tumors or cancer of the MEDIASTINUM. Cancer of Mediastinum,Mediastinal Cancer,Cancer of the Mediastinum,Mediastinum Cancer,Mediastinum Neoplasms,Neoplasms, Mediastinal,Cancer, Mediastinal,Cancer, Mediastinum,Cancers, Mediastinal,Cancers, Mediastinum,Mediastinal Cancers,Mediastinal Neoplasm,Mediastinum Cancers,Mediastinum Neoplasm,Neoplasm, Mediastinal,Neoplasm, Mediastinum,Neoplasms, Mediastinum
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004854 Herpesvirus 4, Human The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies. Burkitt Herpesvirus,Burkitt Lymphoma Virus,E-B Virus,EBV,Epstein-Barr Virus,Human Herpesvirus 4,Infectious Mononucleosis Virus,Burkitt's Lymphoma Virus,HHV-4,Herpesvirus 4 (gamma), Human,Burkitts Lymphoma Virus,E B Virus,E-B Viruses,Epstein Barr Virus,Herpesvirus, Burkitt,Infectious Mononucleosis Viruses,Lymphoma Virus, Burkitt,Mononucleosis Virus, Infectious,Mononucleosis Viruses, Infectious
D006566 Herpesviridae Infections Virus diseases caused by the HERPESVIRIDAE. Herpesvirus Infections,B Virus Infection,Infections, Herpesviridae,Infections, Herpesvirus,B Virus Infections,Herpesviridae Infection,Herpesvirus Infection,Infection, B Virus,Infection, Herpesviridae,Infection, Herpesvirus,Infections, B Virus
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

V Meignin, and A Devergie, and P Brice, and O Brison, and N Parquet, and P Ribaud, and I Cojean, and P Gaulard, and E Gluckman, and G Socie, and A Janin
Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
March 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
V Meignin, and A Devergie, and P Brice, and O Brison, and N Parquet, and P Ribaud, and I Cojean, and P Gaulard, and E Gluckman, and G Socie, and A Janin
[Donor leukocyte transfusion for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation].
April 2000, [Rinsho ketsueki] The Japanese journal of clinical hematology,
V Meignin, and A Devergie, and P Brice, and O Brison, and N Parquet, and P Ribaud, and I Cojean, and P Gaulard, and E Gluckman, and G Socie, and A Janin
T-cell large granular lymphocyte leukemia of donor origin after allogeneic bone marrow transplantation.
October 2003, American journal of clinical pathology,
V Meignin, and A Devergie, and P Brice, and O Brison, and N Parquet, and P Ribaud, and I Cojean, and P Gaulard, and E Gluckman, and G Socie, and A Janin
A Philadelphia chromosome positive acute lymphoblastic leukemia of donor origin after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase.
June 2000, Bone marrow transplantation,
V Meignin, and A Devergie, and P Brice, and O Brison, and N Parquet, and P Ribaud, and I Cojean, and P Gaulard, and E Gluckman, and G Socie, and A Janin
Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation.
March 1992, Blood,
V Meignin, and A Devergie, and P Brice, and O Brison, and N Parquet, and P Ribaud, and I Cojean, and P Gaulard, and E Gluckman, and G Socie, and A Janin
Donor leukemia following allogeneic bone marrow transplantation.
April 1994, Leukemia,
V Meignin, and A Devergie, and P Brice, and O Brison, and N Parquet, and P Ribaud, and I Cojean, and P Gaulard, and E Gluckman, and G Socie, and A Janin
Host origin of bone marrow fibroblasts following allogeneic bone marrow transplantation for chronic myeloid leukemia.
September 1992, Bone marrow transplantation,
V Meignin, and A Devergie, and P Brice, and O Brison, and N Parquet, and P Ribaud, and I Cojean, and P Gaulard, and E Gluckman, and G Socie, and A Janin
Leukemia relapse in donor cells after allogeneic bone-marrow transplantation.
March 1981, The New England journal of medicine,
V Meignin, and A Devergie, and P Brice, and O Brison, and N Parquet, and P Ribaud, and I Cojean, and P Gaulard, and E Gluckman, and G Socie, and A Janin
Donor origin of circulating endothelial progenitors after allogeneic bone marrow transplantation.
January 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
V Meignin, and A Devergie, and P Brice, and O Brison, and N Parquet, and P Ribaud, and I Cojean, and P Gaulard, and E Gluckman, and G Socie, and A Janin
[Donor leukocyte transfusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation].
June 1998, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Copied contents to your clipboard!